Advancing Early Detection in Liver Cancer to Save Lives
Saving Lives through early detection of liver cancer through their propetry test Episcreen Liver.
About Tvaster Genkalp
Tvaster Genkalp is a pioneering healthtech company focused on innovating liver cancer diagnostics through its proprietary liquid biopsy platform. Their flagship product, Episcreen Liver, is a hypermethylation-based diagnostic test for early and accurate detection of Hepatocellular Carcinoma (HCC), the most common form of liver cancer.
Breakthrough Technology: Tvaster’s liquid biopsy detects liver cancer through epigenetic hypermethylation markers, offering a more accurate and stable alternative to traditional genetic mutation-based assays.
Clinical Performance: Tested over 600 patients, Episcreen Liver has demonstrated 91% sensitivity and 88% specificity with high detection rates across all stage.
Full Diagnostic Suite: In addition to HCC, Tvaster has also developed diagnostics for bile cancer and pediatric liver cancer.
Clinical Applications: The technology not only supports early detection but also supports recurrence monitoring post treatment and potential use as a companion diagnostic for pharma partners in liver cancer therapeutics.
Meet the Founders:
Fund II
BioTech
Where We Fuel Innovation and Sustainable Growth
We partner with visionary founders across these industries, bridging bold ideas with resources for real-world impact and lasting change.
Stay Inspired with Our Latest Articles
Explore insights and stories that fuel startup innovation through our curated articles and expert perspectives.
Ready to Build the Future Together?
Let’s turn your bold ideas into transformative realities. with Ideaspring Capital to scale innovation, accelerate growth, and make a lasting impact in the world of technology.
